#United States #New York #Class Action #MoonLake Immunotherapeutics #NASDAQ MLTX

MoonLake Immunotherapeutics Class Action Information

On November 10, 2025, The Gross Law Firm provided crucial updates for shareholders of MoonLake Immunotherapeutics, a company listed on NASDAQ under the ticker MLTX. The firm reminds investors that a class action lawsuit is pending, and shareholders who acquired shares during a specified period are encouraged to act promptly.

Important Details for Shareholders

The law firm has detailed the critical class period spanning from March 10, 2024, to September 29, 2025. During this time, the complaint points to the issuance of potentially false and misleading statements by the company regarding its drug candidates, specifically highlighting issues pertaining to its lead candidate, SLK, and its comparison with BIMZELX.

Allegations Against MoonLake

The allegations assert that the defendants failed to disclose important information, including:
1. Shared Targets: Both SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F, raising questions about the uniqueness of SLK.
2. Lack of Superior Clinical Benefit: Evidence suggests that SLK's Nanobody structure does not offer better clinical outcomes compared to the monoclonal antibody structure of BIMZELX, challenging earlier optimistic developments.
3. Inadequate Tissue Penetration Claims: Claims regarding SLK's supposed increased tissue penetration do not guarantee enhanced clinical efficacy, which the lawsuit argues was not fairly represented.
4. Misleading Statements: Due to the previous points, the defendants allegedly lacked a sound basis for their public statements praising SLK's effectiveness over traditional monoclonal antibodies.

Deadline for Participation

For shareholders wishing to register for this class action, the deadline is set for December 15, 2025. Interested parties are urged to promptly register, regardless of whether they wish to become lead plaintiffs. It's important to note that enrollment in the lawsuit is free of charge. Once registered, participants will receive updates through a case monitoring system.

Why Choose The Gross Law Firm?

The Gross Law Firm has built a reputation as a national leader in class action litigation, focusing on protecting the rights and interests of investors who have been misled by false statements or corporate misconduct. Their commitment to social responsibility and ethical practices emphasizes their role in holding companies accountable.

How to Register

Shareholders can initiate their registration via the following link: Register Here. This process ensures that all investors involved are informed and protected regarding this lawsuit.

If you have any questions or require further assistance, you can contact The Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This situation continues to develop, and affected shareholders should remain alert for any additional updates as the lawsuit proceeds.